vTv Therapeutics Inc.VTVTNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
71.09%
↑ 1166% above average
Average (39q)
5.62%
Historical baseline
Range
High:126.78%
Low:-68.61%
CAGR
+2.7%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 71.09% |
| Q2 2025 | 44.98% |
| Q1 2025 | 26.68% |
| Q4 2024 | -30.71% |
| Q3 2024 | -6.25% |
| Q2 2024 | 29.82% |
| Q1 2024 | 23.90% |
| Q4 2023 | -24.29% |
| Q3 2023 | -39.80% |
| Q2 2023 | 19.00% |
| Q1 2023 | -0.55% |
| Q4 2022 | 29.75% |
| Q3 2022 | 38.55% |
| Q2 2022 | -29.62% |
| Q1 2022 | -42.00% |
| Q4 2021 | 126.78% |
| Q3 2021 | -2.26% |
| Q2 2021 | -21.46% |
| Q1 2021 | 22.45% |
| Q4 2020 | 43.33% |
| Q3 2020 | -29.53% |
| Q2 2020 | -40.32% |
| Q1 2020 | -4.58% |
| Q4 2019 | 20.28% |
| Q3 2019 | -13.36% |
| Q2 2019 | 49.82% |
| Q1 2019 | 0.79% |
| Q4 2018 | 3.78% |
| Q3 2018 | -68.61% |
| Q2 2018 | -3.90% |
| Q1 2018 | -11.17% |
| Q4 2017 | 12.00% |
| Q3 2017 | -6.59% |
| Q2 2017 | -12.20% |
| Q1 2017 | -1.25% |
| Q4 2016 | -0.59% |
| Q3 2016 | -8.10% |
| Q2 2016 | 7.18% |
| Q1 2016 | 26.70% |
| Q4 2015 | 24.96% |